Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from CD24-dependent innate immune checkpoint targeting chimera disrupts TGF-β-driven immunosuppression to enhance anti-tumor therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
2024 · External reference
Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma
2025 · External reference
Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies
2026 · External reference
The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities
10.1038/s41571-025-01077-z · 2025 · External reference
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
2023 · External reference
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
2023 · External reference
TGF-β signaling in health and disease
2023 · External reference
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
2025 · External reference
10.1002/eji.200939201
10.1002/eji.200939201 · External reference
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
2015 · External reference
10.1038/s41568-021-00413-6
10.1038/s41568-021-00413-6 · External reference
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
2020 · External reference
Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications
2025 · External reference
TGF-β signaling: critical nexus of fibrogenesis and cancer
2024 · External reference
10.1038/s41586-019-1456-0
10.1038/s41586-019-1456-0 · External reference
10.1038/s41568-019-0193-x
10.1038/s41568-019-0193-x · External reference
Inhibiting phagocytosis
10.1038/s41590-019-0485-z · 2019 · External reference
Transforming Growth Factor-β1 as a Biomarker of Malignant Behavior and PD-L1 Expression in Thymic Epithelial Tumors
10.1111/cas.70243 · 2026 · External reference
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
10.1038/s41467-017-02696-6 · 2018 · External reference
10.1002/1878-0261.13146
10.1002/1878-0261.13146 · External reference
10.1136/jitc-2021-004122
10.1136/jitc-2021-004122 · External reference
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
2023 · External reference
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC
10.1097/hep.0000000000001054 · 2025 · External reference
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
10.1093/oncolo/oyac254 · 2023 · External reference
Development of TGF-beta signalling inhibitors for cancer therapy
2024 · External reference
TGFβ-Directed Therapeutics: 2020
10.1016/j.pharmthera.2020.107666 · 2021 · External reference
10.1101/cshperspect.a022301
10.1101/cshperspect.a022301 · External reference
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
10.3389/fcell.2020.00605 · 2020 · External reference
10.7150/ijbs.4564
10.7150/ijbs.4564 · External reference
10.1016/j.immuni.2018.03.037
10.1016/j.immuni.2018.03.037 · External reference
10.1172/jci1112
10.1172/jci1112 · External reference
10.1007/s00281-018-0698-5
10.1007/s00281-018-0698-5 · External reference
10.1016/j.immuni.2014.06.010
10.1016/j.immuni.2014.06.010 · External reference
10.1038/s12276-021-00568-0
10.1038/s12276-021-00568-0 · External reference
10.1038/nri3862
10.1038/nri3862 · External reference
10.1007/s10238-025-01937-z
10.1007/s10238-025-01937-z · External reference
